Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Synthetic gabapentinoids, exemplified by gapapentin and pregabalin, are in extensive clinical use for indications including epilepsy, neuropathic pain, anxiety, and alcohol withdrawal. Their mechanisms of action are incompletely understood, but are thought to involve inhibition of α2δ subunit–containing voltage-gated calcium channels. Here, we report that gabapentin is a potent activator of the heteromeric KCNQ2/3 voltage-gated potassium channel, the primary molecular correlate of the neuronal M-current, and also homomeric KCNQ3 and KCNQ5 channels. In contrast, the structurally related gabapentinoid, pregabalin, does not activate KCNQ2/3, and at higher concentrations (≥10 µM) is inhibitory. Gabapentin activation of KCNQ2/3 (EC50 = 4.2 nM) or homomeric KCNQ3* (EC50 = 5.3 nM) channels requires KCNQ3-W265, a conserved tryptophan in KCNQ3 transmembrane segment 5. Homomeric KCNQ2 or KCNQ4 channels are insensitive to gabapentin, whereas KCNQ5 is highly sensitive (EC50 = 1.9 nM). Given the potent effects and the known anticonvulsant, antinociceptive, and anxiolytic effects of M-channel activation, our findings suggest the possibility of an unexpected role for M-channel activation in the mechanism of action of gabapentin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SwissDock, a protein-small molecule docking web service based on EADock DSS
Grosdidier, A., Zoete, V., & Michielin, O. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr366 · Cited by 1,950
Gabapentin for the treatment of alcohol use disorder
Mason, B. J., Quello, S., & Shadan, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417383 · Cited by 104 · cited 1×
“Because of the structural similarities between gabapentinoids andGABA, and the known influence of theM-current inmany of the disease states responsive to gabapentinoids (epilepsy, pain, anxiety, and alcohol withdrawal) (Blackburn-Munro et al., 2005; Kang et al., 2017; Mason et al., 2018), we hypothesized that gabapent…”
Background
Cited by
Chemical modulation of Kv7 potassium channels
Borgini, M., Mondal, P., Liu, R., & Wipf, P. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00328j · Cited by 37
Ostacolo, C., Miceli, F., Di Sarno, V., Nappi, P., Iraci, N., Soldovieri, M. V., Ciaglia, T., Ambrosino, P., Vestuto, V., Lauritano, A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00796 · Cited by 39
Pharmacological Manipulation of Kv7 Channels as a New Therapeutic Tool for Multiple Brain Disorders
Vigil, F. A., Carver, C. M., & Shapiro, M. S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00688 · Cited by 36
Liu, Y., Bian, X., & Wang, K. (2021) · Handbook of Experimental Pharmacology · doi:10.1007/164_2021_458 · Cited by 36
Presynaptic antiseizure medications-basic mechanisms and clues for their rational combinations
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00603-7 · Cited by 13
“Thus, it was reported that gabapentin is a potent activator of the heteromeric KCNQ2/3 voltage-gated potassium channel and the homomeric KCNQ3 and KCNQ5 channels, whereas pre-gabalin at higher concentrations displays opposite effects [125].”
Background
Metadata
- Authors
- Manville, R. W., & Abbott, G. W.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 94
- Issue
- 4
- Pages
- 1155-1163
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2883140356
- Cited by
- 67
- References
- 2
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.